Marimaca Copper Completes A$80,000,000 Bookbuild
Globenewswire· 2025-09-05 13:00
Not for release to U.S. wire services or for distribution in the United States VANCOUVER, British Columbia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (TSX: MARI) (ASX: MC2) (“Marimaca” or the “Company”) is pleased to announce that it has secured binding commitments for a brokered placement in Australia and select other jurisdictions, excluding Canada, of 8,247,423 new Chess Depositary Interests (“CDI”) of the Company at a price of A$9.70 per CDI for gross proceeds of approximately A$80,000,00 ...
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Globenewswire· 2025-09-05 13:00
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a favorable s ...
Legacy Education Inc. (LGCY) to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Prnewswire· 2025-09-05 13:00
LANCASTER, Calif., Sept. 5, 2025 /PRNewswire/ -- Legacy Education Inc. ("Legacy Education" or the "Company") (NYSE American: LGCY), a leading provider of career-focused education and training, today announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference taking place Monday, September 8 through Wednesday, September 10, 2025, at Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY. The conference highlights emerging trends and innovations in global investment mark ...
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Newsfilter· 2025-09-05 13:00
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a favorable sa ...
Robot Consulting Co., Ltd. Engages Former bitFlyer Holdings CEO Masaaki Seki as to Advise on Ethereum Investment Strategy and Finance
Globenewswire· 2025-09-05 13:00
Tokyo, Japan, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Robot Consulting Co., Ltd. (Nasdaq: LAWR) (the “Company” or “Robot Consulting”), a Japanese platform service provider focusing on human resource solutions with an intention to expand into legal technology and the metaverse, today announced that the Company has engaged Mr. Masaaki Seki, a former representative director of bitFlyer Holdings, Inc. (“bitFlyer Holdings”) and bitFlyer, Inc. (“bitFlyer”), to advise on its Ethereum investment strategy and finance obj ...
Virbac : Declaration of the number of shares and voting rights 08/2025
Globenewswire· 2025-09-05 12:45
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsAugust, 31 20258 390 660Gross total of voting rights : 12 705 441Net total* of voting rights ...
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)
Globenewswire· 2025-09-05 12:45
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward Phase 2 IND submissions in Q1 2026 Carlsbad, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and ...
Orbit International Reports Consolidated Bookings of Approximately $2,400,000 for Month of August
Globenewswire· 2025-09-05 12:45
Strong Bookings Due Primarily to Large Orders Received During Month by Power GroupHAUPPAUGE, N.Y., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Orbit International Corp. (the “Company”) (OTCID Basic Market:ORBT), an electronics manufacturer and software solution provider, today announced that for the month of August 2025, consolidated bookings were approximately $2,400,000. The strong booking month was primarily due to bookings recorded by its Orbit Power Group (“OPG”) in excess of $1,700,000, which included a previo ...
NeoVolta to Debut New NV16kW AC Hybrid Inverter with 24kW PV Input at RE+ 2025 in Las Vegas
Globenewswire· 2025-09-05 12:45
Latest innovation delivers more power and solar integration, setting a new standard for clean energy storage solutions.SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NeoVolta Inc. (NASDAQ: NEOV), a U.S.-based energy technology company delivering scalable storage, for resilient residential and commercial power infrastructure, today announced will unveil its newest innovation—the NV16kW AC hybrid inverter—at the RE+ 2025 clean energy trade show in Las Vegas. The product launch will take place at Booth V12313, ...
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
Globenewswire· 2025-09-05 12:45
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September. Details are as follows: ADC and Novel Conjugates Partnering and Investment Summit ...